These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32801898)

  • 1. Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis.
    Zhang X; Huang H; Wei Z; Zhu Z; Yang D; Fu H; Xu J; Hu Z; Zhang Y; You Q; Huang X; Yan R; Wang W; Cai Q
    Cancer Manag Res; 2020; 12():6641-6653. PubMed ID: 32801898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis.
    Zhang X; Huang H; Yang D; Wang P; Huang X; Hu Z; Zhang Y; Yan R; Zhu Z; Cai Q
    Technol Cancer Res Treat; 2021; 20():15330338211036310. PubMed ID: 34328799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
    BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 7. Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA).
    Cui Y; Yu Y; Zheng S; Ying J; Du Y; Wang Y; Wang X; Shen Z; Liu F; Lv M; Sun Y; Liu T
    BMC Cancer; 2023 Apr; 23(1):308. PubMed ID: 37016303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
    Zhang C; Wu B; Yang H; Yao Z; Zhang N; Tan F; Liu M; Xu K; Chen L; Xing J; Cui M; Su X
    BMC Cancer; 2022 Nov; 22(1):1223. PubMed ID: 36443694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.
    Ma J; Yao S; Li XS; Kang HR; Yao FF; Du N
    Medicine (Baltimore); 2015 Oct; 94(42):e1489. PubMed ID: 26496252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 11. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis.
    Wang K; Ren Y; Ma Z; Li F; Cheng X; Xiao J; Zhang S; Yu Z; Yang H; Zhou H; Li Y; Liu H; Jiao ZY
    Cancer Manag Res; 2019; 11():3009-3020. PubMed ID: 31114348
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer.
    Zhang Y; Zhang B; Yang J; Zhang J; Zhang W
    Cancer Manag Res; 2021; 13():2279-2286. PubMed ID: 33732020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
    Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
    Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
    Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
    Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
    Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy
    Xu W; Wang L; Yan C; He C; Lu S; Ni Z; Hua Z; Zhu Z; Sah BK; Yang Z; Zheng Y; Feng R; Li C; Yao X; Chen M; Liu W; Yan M; Zhu Z
    Front Oncol; 2021; 11():718556. PubMed ID: 34497768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.
    Iwatsuki M; Orita H; Kobayashi K; Hidaka S; Arigami T; Kusumoto T; Satake H; Oki E; Tsutsumi S; Tobimatsu K; Shimokawa M; Saeki H; Makiyama A; Baba H; Mori M
    Gastric Cancer; 2022 Jan; 25(1):180-187. PubMed ID: 34379229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
    Wang Z; He T; Yu D; Qin X; Geng A; Yang H
    Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis.
    Chen Y; He J; Liu D; Xiao J; Chen X; Tang H; Luo D; Shang C; Lian L; Peng J
    BMC Cancer; 2021 Dec; 21(1):1328. PubMed ID: 34903191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.